The Cremins lab investigates the epigenetic mechanisms regulating development and function of the mammalian central nervous system. We map and analyze neuronal epigenomes in three-dimensions using quantitative, genome-wide technologies. We also perturb epigenomes by employing state-of-the art genetic engineering strategies (e.g. CRISPR/Cas9, optoepigenetics). To test our hypotheses, we primarily use embryonic and induced pluripotent stem cell models of neuronal differentiation and disease. Our long-term goal is to discover how genome architecture controls genome function, applying this to study fundamental mechanisms controlling neuronal phenotype and, by extension, the onset and progression of neurodegenerative and neurodevelopmental disease states.

Alexandria Nikish joins the lab for her Ph.D. studies in Fall 2020. Ali
did her undergraduate degree at MIT and worked at the Broad Institute as 
well as CRISPR Therapeutics. Welcome, Ali!

Katelyn Titus is accepted into the Bioengineering Ph.D. program and will 
transition to a full time graduate student in our lab in Fall 2019. 
Congratulations Kate!

Congratulations to Linda Zhou on receiving her F31 NIH grant.

Congratulations to Kate Titus on her acceptance into the Bioengineering 
PhD program at UPenn. Kate – we are proud of you!

Thomas Gilgenast’s manuscript was accepted at Cell Systems. 
Congratulations Thomas!

We welcome Harshini Chandrashekar to the lab. Welcome, Harshini!

Kate Titus is accepted into the Genomics and Computational Biology Ph.D. 
program. Congratulations Kate!



Our work is supported by the New York Stem Cell Foundation, the Alfred P. Sloan Foundation, the National Science Foundation, an NIH New Innovator Award through the National Institute of Mental Health and the NIH 4D Nucleome Common Fund Initiative.